المؤلفون: Alexia Iasonos, Keith L. Knutson, Yanyun Li, Roisin E. O'Cearbhaill, Jean Torrisi, Lewis Chesebrough, Taha Merghoub, Courtney L. Erskine, Mathew S Block, Jason A. Konner, Rachel N. Grisham, Travis J. Hollmann, Autumn S. McDonnell, Dmitriy Zamarin, Carol Aghajanian, Sven Walderich, Aliya Holland, Jacqueline Gallagher, Qin Zhou

المصدر: Journal for Immunotherapy of Cancer

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, Durvalumab, Non-Randomized Controlled Trials as Topic, clinical trials, phase II as topic, Antineoplastic Agents, Immunological, 0302 clinical medicine, Tumor Microenvironment, Immunology and Allergy, Ovarian Neoplasms, education.field_of_study, Immunogenicity, Antibodies, Monoclonal, Middle Aged, Prognosis, Gene Expression Regulation, Neoplastic, Survival Rate, Vaccination, Treatment Outcome, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Molecular Medicine, Drug Therapy, Combination, Female, Adult, Folate Receptor Alpha, medicine.medical_specialty, T cell, Immunology, Population, immunogenicity, vaccine, Cancer Vaccines, programmed cell death 1 receptor, 03 medical and health sciences, Immune system, Internal medicine, Biomarkers, Tumor, medicine, Humans, Folate Receptor 1, education, Aged, Pharmacology, Tumor microenvironment, business.industry, Clinical Trials Monitor, Cystadenocarcinoma, Serous, Endometrial Neoplasms, 030104 developmental biology, antigens, neoplasm, business, Adenocarcinoma, Clear Cell, Follow-Up Studies

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eac64e64a8202e3e031b292b42295d80
https://doi.org/10.1136/jitc-2020-000829